The use of targeted intra-operative radiotherapy (TARGIT), as a single dose – with ZEISS INTRABEAM – directly after removal of a tumor, is confirmed as non-inferior, when compared with external beam radiotherapy (EBRT). The TARGIT-A study further is the largest international multicenter study with a follow-up time of 8.6 years. In addition to its effectiveness, the IORT technique is demonstrating its cost efficiency. But will this be enough to now also develop further clinical treatment standards and reflect this in the guidelines?

Please join us in hearing the breast surgeon Professor Michael Alvarado, the radiation oncologists Professor William Small and Dr. Valery Uhl discussing this elemental question, based on this latest clinical milestone.

Tuesday, October 13, 2020
9:00 – 10:00 AM CEST | 3:00 – 04:00 AM EDT
4:00 – 5:00 PM CEST | 10:00 – 11:00 AM EDT